Malaria is a mosquito-borne disease that can cause infected people to become very sick with high fever, chills, and flu-like illness. It can also cause death. Substantial progress has been made globally to control and eliminate malaria, but it continues to be a significant public health problem with roughly 3.2 billion people worldwide at risk for the disease.
Why Is the Study of Malaria a Priority for NIAID?
Roughly 3.2 billion people—almost half of the world’s population—are at risk of malaria, according to the World Health Organization. Although substantial progress has been made in the fight to control and eliminate malaria, the mosquito-borne disease remains a significant public health problem.
How Is NIAID Addressing This Critical Topic?
NIAID is the lead agency in the U.S. federal government supporting malaria research and development. The Institute has a longstanding commitment to malaria research to support the goals of reducing morbidity and mortality from malaria and ultimately eradicating the disease. NIAID is conducting and supporting research to better understand the disease, develop effective alternatives to mosquito control, and create diagnostics, treatments, and a vaccine to prevent infection.
Latest News Releases
Newly Described Human Antibody Prevents Malaria in Mice, March 19, 2018
Disease Resistance Successfully Spread from Modified to Wild Mosquitoes, September 28, 2017
NIAID Now Blog
Genetic Study Reveals Origins of Hard-to-Treat Malaria, February 5, 2018